IA
VRTX icon

IFP Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

IFP Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Buy
2,968
+248
+9% +$110K 0.03% 590
2026
Q1 		$1.21M Sell
2,720
-362
-12% -$169K 0.03% 606
2025
Q4 		$1.4M Buy
3,082
+797
+35% +$344K 0.03% 532
2025
Q3 		$895K Buy
2,285
+695
+44% +$290K 0.02% 648
2025
Q2 		$800K Sell
1,590
-1,074
-40% -$495K 0.02% 651
2025
Q1 		$1.3M Sell
2,664
-92
-3% -$42.9K 0.04% 479
2024
Q4 		$1.11M Buy
2,756
+909
+49% +$421K 0.04% 501
2024
Q3 		$859K Sell
1,847
-457
-20% -$220K 0.03% 517
2024
Q2 		$1.08M Buy
2,304
+328
+17% +$142K 0.04% 422
2024
Q1 		$826K Sell
1,976
-159
-7% -$67.2K 0.04% 460
2023
Q4 		$869K Buy
2,135
+354
+20% +$131K 0.04% 417
2023
Q3 		$619K Sell
1,781
-73
-4% -$25.5K 0.03% 520
2023
Q2 		$652K Buy
1,854
+289
+18% +$97.4K 0.03% 558
2023
Q1 		$238K Sell
1,565
-5,339
-77% -$1.6M 0.01% 878
2022
Q4 		$1.1M Sell
6,904
-1,343
-16% -$409K 0.03% 590
2022
Q3 		$1.29M Buy
8,247
+711
+9% +$205K 0.03% 550
2022
Q2 		$1.17M Hold
7,536
– – 0.04% 531
2022
Q1 		$1.17M Buy
7,536
+6,426
+579% +$1.53M 0.04% 531
2021
Q4 		$245K Sell
1,110
-54
-5% -$10.5K ﹤0.01% 863
2021
Q3 		$213K Buy
1,164
+154
+15% +$30.1K ﹤0.01% 925
2021
Q2 		$198K Sell
1,010
-814
-45% -$170K ﹤0.01% 913
2021
Q1 		$400K Sell
1,824
-421
-19% -$92.5K 0.01% 593
2020
Q4 		$533K Buy
2,245
+19
+0.9% +$4.36K 0.02% 488
2020
Q3 		$613K Buy
2,226
+945
+74% +$261K 0.04% 388
2020
Q2 		$372K Buy
1,281
+286
+29% +$77.5K 0.03% 478
2020
Q1 		$223K Buy
995
+309
+45% +$70.9K 0.02% 544
2019
Q4 		$152K Sell
686
-66
-9% -$13.4K 0.01% 759
2019
Q3 		$125K Buy
+752
New +$133K 0.01% 956
2019
Q1 		$83K Sell
452
-954
-68% -$176K 0.01% 760
2018
Q4 		$227K Sell
1,406
-230
-14% -$39.9K 0.01% 814
2018
Q3 		$315K Buy
1,636
+577
+54% +$103K 0.01% 869
2018
Q2 		$180K Buy
1,059
+345
+48% +$53.5K 0.01% 1119
2018
Q1 		$107K Hold
714
– – ﹤0.01% 1345
2017
Q4 		$107K Sell
714
-148
-17% -$21.9K ﹤0.01% 1355
2017
Q3 		$131K Buy
862
+158
+22% +$23.8K 0.01% 1393
2017
Q2 		$91K Sell
704
-2
-0.3% -$241 ﹤0.01% 1574
2017
Q1 		$77K Sell
706
-65
-8% -$5.72K ﹤0.01% 1671
2016
Q4 		$57K Buy
771
+108
+16% +$8.79K ﹤0.01% 1807
2016
Q3 		$58K Sell
663
-9
-1% -$851 ﹤0.01% 1717
2016
Q2 		$58K Buy
672
+220
+49% +$19K ﹤0.01% 1683
2016
Q1 		$83K Sell
452
-315
-41% -$28.5K 0.01% 759
2015
Q4 		$97K Buy
+767
New +$92.6K 0.01% 1195

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

IFP Advisors's VRTX Position: Q2 2026 in Review

IFP Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 9.1% in Q2 2026, buying an estimated $110K and bringing the position to 2,968 shares worth $1.47M. The position accounts for 0.03% of the portfolio, ranked #590.

IFP Advisors first reported a position in VRTX in Q4 2015 and has held it in 42 quarters since. 327 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • IFP Advisors held 2,968 shares of Vertex Pharmaceuticals worth $1.47M as of Q2 2026.
  • IFP Advisors bought 248 Vertex Pharmaceuticals shares in Q2 2026, an estimated $110K.
  • Vertex Pharmaceuticals made up 0.03% of IFP Advisors's portfolio in Q2 2026, its #590 holding.
  • IFP Advisors first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
  • 327 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.